Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

Simple item page
dc.contributor.authorErkurt M.A.
dc.contributor.authorBerber I.
dc.contributor.authorTekgündüz E.
dc.contributor.authorDogu M.H.
dc.contributor.authorKorkmaz S.
dc.contributor.authorDemir C.
dc.contributor.authorYilmaz M.
dc.contributor.authorAkay O.M.
dc.contributor.authorPala C.
dc.contributor.authorBilen Y.
dc.contributor.authorKaya E.
dc.contributor.authorSari I.
dc.contributor.authorSencan M.
dc.contributor.authorKuku I.
dc.contributor.authorAltuntaş F.
dc.contributor.authorDal M.S.
dc.contributor.authorAydogdu I.
dc.date.accessioned2024-07-22T08:12:07Z
dc.date.available2024-07-22T08:12:07Z
dc.date.issued2016
dc.description.abstractWe investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd.
dc.identifier.DOI-ID10.1016/j.transci.2016.01.018
dc.identifier.issn14730502
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15922
dc.language.isoEnglish
dc.publisherElsevier Ltd
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCentral Nervous System Neoplasms
dc.subjectDemography
dc.subjectHumans
dc.subjectLymphoma
dc.subjectMiddle Aged
dc.subjectPractice Patterns, Physicians'
dc.subjectRecurrence
dc.subjectRetrospective Studies
dc.subjectStem Cell Transplantation
dc.subjectTransplantation, Autologous
dc.subjectYoung Adult
dc.subjectbusulfan
dc.subjectcyclophosphamide
dc.subjectcytarabine
dc.subjectetoposide
dc.subjectmelphalan
dc.subjectthiotepa
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectautologous stem cell transplantation
dc.subjectcancer chemotherapy
dc.subjectcancer prognosis
dc.subjectcancer radiotherapy
dc.subjectfemale
dc.subjectfollow up
dc.subjectgeneral practice
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical record review
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectoverall survival
dc.subjectprimary central nervous system lymphoma
dc.subjectrecurrence free survival
dc.subjectrelapse
dc.subjectremission
dc.subjectretrospective study
dc.subjectvery elderly
dc.subjectautotransplantation
dc.subjectCentral Nervous System Neoplasms
dc.subjectclinical practice
dc.subjectclinical trial
dc.subjectdemography
dc.subjectlymphoma
dc.subjectmiddle aged
dc.subjectrecurrent disease
dc.subjectstem cell transplantation
dc.subjectyoung adult
dc.titlePrimary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu